Elevation Point Wealth Partners LLC Trims Stake in DexCom, Inc. $DXCM

Elevation Point Wealth Partners LLC lessened its position in shares of DexCom, Inc. (NASDAQ:DXCM) by 45.4% during the second quarter, HoldingsChannel reports. The institutional investor owned 4,325 shares of the medical device company’s stock after selling 3,590 shares during the quarter. Elevation Point Wealth Partners LLC’s holdings in DexCom were worth $378,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors also recently added to or reduced their stakes in DXCM. Quadrant Capital Group LLC boosted its holdings in shares of DexCom by 34.1% in the second quarter. Quadrant Capital Group LLC now owns 9,583 shares of the medical device company’s stock valued at $837,000 after acquiring an additional 2,437 shares during the period. Vinva Investment Management Ltd purchased a new stake in DexCom in the 2nd quarter valued at $604,000. MIG Capital LLC acquired a new stake in DexCom during the 2nd quarter worth $63,215,000. Rhenman & Partners Asset Management AB grew its position in DexCom by 2.9% during the 2nd quarter. Rhenman & Partners Asset Management AB now owns 159,500 shares of the medical device company’s stock worth $13,923,000 after purchasing an additional 4,500 shares during the last quarter. Finally, SlateStone Wealth LLC purchased a new position in DexCom during the 2nd quarter worth $239,000. Institutional investors and hedge funds own 97.75% of the company’s stock.

Insider Buying and Selling

In other DexCom news, EVP Sadie Stern sold 1,466 shares of the business’s stock in a transaction on Thursday, September 4th. The shares were sold at an average price of $80.00, for a total transaction of $117,280.00. Following the sale, the executive vice president directly owned 105,223 shares in the company, valued at approximately $8,417,840. The trade was a 1.37% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Richard Alexander Collins sold 2,906 shares of the company’s stock in a transaction on Friday, November 14th. The stock was sold at an average price of $59.05, for a total transaction of $171,599.30. Following the transaction, the director directly owned 35,088 shares in the company, valued at approximately $2,071,946.40. This trade represents a 7.65% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 9,999 shares of company stock valued at $619,391 in the last quarter. Corporate insiders own 0.32% of the company’s stock.

DexCom Stock Performance

NASDAQ DXCM opened at $63.46 on Friday. The stock has a market capitalization of $24.75 billion, a price-to-earnings ratio of 44.07, a PEG ratio of 1.43 and a beta of 1.40. The business’s 50 day moving average is $64.31 and its two-hundred day moving average is $75.83. DexCom, Inc. has a 12-month low of $54.11 and a 12-month high of $93.25. The company has a current ratio of 1.52, a quick ratio of 1.35 and a debt-to-equity ratio of 0.48.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings results on Thursday, October 30th. The medical device company reported $0.61 EPS for the quarter, beating the consensus estimate of $0.57 by $0.04. DexCom had a return on equity of 30.41% and a net margin of 13.29%.The business had revenue of $1.21 billion during the quarter, compared to analysts’ expectations of $1.18 billion. During the same period last year, the firm earned $0.45 EPS. The company’s quarterly revenue was up 21.6% compared to the same quarter last year. DexCom has set its FY 2025 guidance at EPS. Research analysts expect that DexCom, Inc. will post 2.03 EPS for the current year.

Analyst Upgrades and Downgrades

DXCM has been the subject of a number of research reports. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of DexCom in a report on Monday, November 24th. Sanford C. Bernstein reaffirmed an “outperform” rating and set a $84.00 price objective on shares of DexCom in a research note on Monday, November 3rd. The Goldman Sachs Group decreased their price objective on DexCom from $104.00 to $89.00 and set a “buy” rating for the company in a research report on Wednesday, October 1st. Barclays set a $80.00 target price on DexCom and gave the company an “equal weight” rating in a research note on Monday, November 3rd. Finally, Oppenheimer cut DexCom from an “outperform” rating to a “market perform” rating in a research note on Monday, September 8th. Three analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $86.73.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.